Guidelines for the treatment of Gaucher disease through the Life Saving Drugs Program

# Life Saving Drugs Program

## About this program

Through the Life Saving Drugs Program (LSDP), the Australian Government provides subsidised access for eligible patients to expensive life-saving medicines.

## Purpose of this document

This document provides guidance for treating physicians with relevant specialist registration who wish to apply for their patients to receive access to subsidised treatment for Gaucher disease (type 1) through the LSDP.

It describes the criteria for general, initial and ongoing eligibility to access subsidised treatment and the administrative requirements associated with the initial application and annual reapplications.

## Treatment of Gaucher disease through the LSDP

Subsidised treatment is available for eligible patients with a confirmed diagnosis of Gaucher disease (type 1). Subsidised treatment through the LSDP is not available for patients with type 2 or type 3 Gaucher disease.

## Medicines currently available for the treatment of Gaucher disease through the LSDP

There are 4 medicines currently subsidised through the LSDP for the treatment of Gaucher disease (type 1).

The generic names for these medicines are imiglucerase, velaglucerase, taliglucerase and eliglustat.

The trade names for these medicines are Cerezyme®, VPRIV®, Elelyso® and Cerdelga®.

The Therapeutic Goods Administration (TGA) registration and Product Information for imiglucerase (Cerezyme®), velaglucerase (VPRIV®), taliglucerase (Elelyso®) and eliglustat (Cerdelga®) can be found on the [TGA's website](http://www.tga.gov.au).

## Choice of treatment

Treating physicians can request the most appropriate medicine to treat their patient, where all eligibility requirements have been met.

All patients who are initiated on a medicine or transitioned to a different medicine through the LSDP are required to remain on the same medicine for a period of at least 12 months, unless there is objective clinical evidence of ongoing clinical deterioration or significant adverse reactions.

## Dosage

The maximum dosage of imiglucerase that is subsidised through the LSDP is 60 U/kg   
per fortnight.

The maximum dosage of velaglucerase that is subsidised through the LSDP is 60 U/kg   
per fortnight.

The maximum dosage of taliglucerase that is subsidised through the LSDP is 60 U/kg   
per fortnight.

Dosage adjustments by down-titration can be made after 12 months for stable adult patients treated with enzyme replacement therapy (ERT). Dosage adjustments should be made on an individual basis, and may increase or decrease, based on achievement of therapeutic goals as assessed by routine comprehensive evaluations of the patient's clinical manifestations.

The LSDP can be advised of dosage adjustments by emailing [lsdp@health.gov.au](mailto:LSDP@health.gov.au).

The maximum dosage of eliglustat that is subsidised through the LSDP is 84mg in an oral capsule twice daily. Before initiation of treatment with eliglustat, patients should be genotyped for CYP2D6 to determine the CYP2D6 metaboliser status (as this will affect the dose).

## Home infusion

If a patient wishes to receive imiglucerase, velaglucerase or taliglucerase through a home infusion service, the patient must have received at least 3 infusions in the hospital setting and have been assessed by the treating physician as medically stable, meaning that any infusion‑associated reactions are well controlled.

# General eligibility requirements

## LSDP funding conditions

A patient must continually meet the LSDP funding conditions to be eligible to receive access to Australian Government–subsidised treatment for Gaucher disease (type 1) through the LSDP.

The current LSDP funding conditions can be found on the [program’s website](https://health.gov.au/initiatives-and-programs/life-saving-drugs-program).

For Gaucher disease, a patient must:

* satisfy the initial and ongoing eligibility criteria as detailed in these guidelines
* participate in the evaluation of effectiveness of the medicine by periodic assessment, as directed by these guidelines, or have an acceptable reason not to participate
* not be suffering from any other medical condition, including complications or sequelae of Gaucher disease (type 1), that might compromise the effectiveness of the treatment
* be an Australian citizen or permanent Australian resident who qualifies for Medicare.

In most cases, participation in a clinical trial will not affect a patient’s eligibility to access LSDP medicines. However, treating physicians are required to advise the LSDP if their patient is participating in a clinical trial.

## Exclusion criteria

The following patients are not eligible for subsidised treatment with imiglucerase, velaglucerase, taliglucerase or eliglustat for the treatment of Gaucher disease (type 1) through the LSDP:

* Asymptomatic patients: the treatment of asymptomatic patients is generally not approved unless the disease is of sufficient severity to suggest a severe course or impending complications (this could be determined through mutation analysis in the asymptomatic patient), or for a patient with a family history of a severe, accelerated course of the disease in childhood.
* Patients with potentially confounding diagnoses, such as Hodgkin lymphoma.
* Patients with irreversible complications of Gaucher disease. In some patients with Gaucher disease, secondary pathologic changes, such as avascular necrosis of bone, may already have occurred that would not be expected to respond to therapy. In such patients, reversal of the pathology is unlikely. Treatment of patients with significant secondary pathology would be directed at preventing further progression of the disease. In these cases, the extent to which symptoms, such as bone pain, are due to active progression of the disease, rather than the secondary pathology, can only be established by a trial of therapy.
* Patients with another life threatening or severe disease where the long‑term prognosis is unlikely to be influenced by therapy.
* Patients with another medical condition that might reasonably be expected to compromise a response to therapy.
* Patients with type 2 or type 3 Gaucher disease.

# Initial eligibility requirements

## Diagnosis

The diagnosis of Gaucher disease (type 1) must have been confirmed by the demonstration of specific deficiency of glucocerebrosidase enzyme activity in leukocytes or cultured skin fibroblasts, and/or by the presence of mutations in the glucocerebrosidase gene, known to result in severe deficiency of enzyme activity, in tissue or peripheral blood leukocytes.

The patient must satisfy at least one of the following criteria to be eligible for treatment with imiglucerase, velaglucerase, taliglucerase or eliglustat:

Symptomatic Gaucher disease (type 1) with any of the disease manifestations listed below:

* **Skeletal complications**: Evidence of skeletal disease beyond mild osteopenia or Erlenmeyer flask deformity, as assessed by symptoms, skeletal survey and MRI.
* **Haematological complications**: Haemoglobin <105g/L for females and <115g/L for males (at least 2 measurements more than one month apart and having excluded other causes, e.g. iron deficiency); or platelet count <120 x109/L on at least 2 occasions (more than one month apart).
* **Gastrointestinal complications**: Liver volume (CT or MRI) 1.25 x normal; or spleen volume (CT or MRI) 5 x normal.
* Patients under 16 years of age with symptomatic Gaucher disease with any relevant physical signs may be treated prior to confirmation of the type of Gaucher disease.

See the [initial application form](https://www.health.gov.au/resources/publications/life-saving-drugs-program-gaucher-disease-type-1-initial-application?language=en).

Testing is not funded or subsidised through the LSDP, however some tests may be subsidised through Medicare or available through the treating public hospital.

## Eliglustat

For treatment with eliglustat, in addition to meeting the above criteria patients must also:

* be aged 18 years and over, and
* have been treated with ERT for at least 12 months or be intolerant to ERT.

Patients should be genotyped for CYP2D6 to determine metaboliser status prior to receiving eliglustat (as this will affect the dose).

If these conditions are met a treating physician can request that a current LSDP patient be switched to eliglustat by providing a clinic letter to the LSDP. A full application is not required for these patients.

# Ongoing eligibility requirements

The treating physician must submit the separate [reapplication form](https://www.health.gov.au/resources/publications/life-saving-drugs-program-pompe-disease-reapplication) to the LSDP by 1 May every year if they wish their patient to continue to receive subsidised treatment through the LSDP.

If a reapplication is not submitted by 1 May each year without a clinical justification, the patient is at risk of having their treatment paused until the reapplication is received.

The reapplication must demonstrate clinical improvement in the patient or stabilisation of the patient's condition, and evidence to support ongoing eligibility for the treatment of Gaucher disease (type 1) must be provided.

The treating physician must declare that the patient continues to meet the eligibility criteria to receive subsidised treatment through the LSDP in accordance with the guidelines.

The clinic letter and test results provided to support the reapplication must be no more than 12 months old at the time of each reapplication and should not have been used to support a previous application or reapplication.

Subsidised treatment may continue unless one or more of the following situations apply:

* failure to comply adequately with treatment or measures
* failure to provide data, copies of test results and the [Excel spreadsheet](https://www.health.gov.au/resources/publications/lsdp-gaucher-patient-test-results-spreadsheet) for Gaucher disease (type 1), evidencing the effectiveness of the therapy. Test results must not be more than 12 months old at the time of reapplication to the LSDP and should not have been used to support a previous application or reapplication
* therapy fails to relieve the symptoms of disease that originally resulted in the patient being approved for subsidised treatment
* development of the following features consistent with a neuronopathic form of Gaucher disease:
* opisthotonus
* seizures
* bulbar dysfunction (manifested by swallowing difficulties)
* deteriorating intellectual function (determined by age-appropriate neuropsychological assessment), or
* deterioration in motor skills.
* for ERT only: the patient has severe infusion-related adverse reactions which are not preventable by appropriate pre-medication and/or adjustment of infusion rates (does not apply for eliglustat)
* the patient develops another life threatening or severe disease where the long-term prognosis is unlikely to be influenced by treatment
* the patient develops another medical condition that might reasonably be expected to compromise a response to treatment
* presentation of conditions listed in the exclusion criteria.

Testing is not funded or subsidised through the LSDP, however some tests may be subsidised through Medicare or available through the treating public hospital.

## Skeletal MRI

Treating physicians may wish to have skeletal MRIs reviewed centrally for patients receiving subsidised therapy through the LSDP to assist with assessment of patient response to therapy.

Treating physicians must indicate which medicine the patient is being treated with when filling out a referral form for a centralised MRI scan review. This will allow an invoice to be generated to the appropriate sponsor.

Costs will be met by the sponsors for an annual centralised skeletal MRI scan review for each Gaucher patient who is receiving subsidised treatment with imiglucerase, velaglucerase, taliglucerase or eliglustat through the LSDP.

The following skeletal MRIs are suggested for a radiology assessment:

* Spine: Sagittal T1 and T2 weighted imaging of the lumbar spine (not fat suppressed); and
* Lower limbs: (hips, femora to proximal tibia) T1 weighted coronal and STIR imaging of the length of both femora (from hips to proximal tibial epiphyses, in 2 scans if necessary, but include the length of the femora in one coronal image if possible).

These images should be saved in DICOM format and sent to the appropriate contact below, based on your patient's age. They can be sent as a downloadable file via email, on a CD or a USB stick. The accompanying letter, disc or USB should be labelled with the patient's name, date of birth, medicine treatment and the date of the MRI examination.

### For adult patients:

**Contact**: Ms Hayley Iengo

**Hospital**: Royal Melbourne Hospital

**Department**: Radiology Department

**Address**: Grattan Street PARKVILLE VIC 3050

**Phone**: (03) 9342 7255

Radiologists: Dr Kapilan Varatharajah, Dr Sarah Kalus

**Email**: [hayley.iengo@mh.org.au](mailto:hayley.iengo@mh.org.au)

### For paediatric patients:

**Contact**: Ms Evelyn Johnson

**Hospital**: The Royal Children's Hospital Melbourne

**Department**: Department of Medical Imaging

**Address**: 50 Flemington Road PARKVILLE VIC 3052

**Phone**: (03) 9345 5237

**Email**: [evelyn.johnson@rch.org.au](mailto:evelyn.johnson@rch.org.au)

# Cessation of treatment

The treating physician should notify the LSDP immediately in writing when a patient ceases treatment, including the reason(s) for treatment cessation.

## Treatment breaks

Treatment breaks of up to 3 months can be taken without the requirement for submission of a new reapplication form to recommence treatment.

Patients who are applying to recommence treatment following a break of longer than 3 months should submit a new [reapplication form](https://health.gov.au/resources/publications/lsdp-pompe-reapplication).